Acadia Pharmaceuticals (ACAD) PT Raised to $70 at Cantor Fitzgerald
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $28.24 --0%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Join SI Premium – FREE
Cantor Fitzgerald analyst Charles Duncan raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $70.00 (from $63.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS
- QBE Insurance Group Ltd. (QBE:AU) (QBEIF) PT Lowered to AUD26.50 at JPMorgan
- CVRx Inc (CVRX) PT Lowered to $5 at Cantor Fitzgerald on Q2 Update Pressures
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Cantor Fitzgerald, Charles DuncanSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
